This study first identified that high expressions of UBE2NL and HIST2H3PS2 were associated with poor survival outcomes in epithelial ovarian cancer (EOC) patients using TCGA data, and we validated these findings in clinical samples across all subtypes of EOC. Here, UBE2NL is linked to ovarian carcinoma.